[Treatment of epidermoid carcinoma of the oro-pharyngo-laryngeal area with combination of methotrexate and bleomycin].
D000368:Aged; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007822:Laryngeal Neoplasms / Q000188:drug therapy*; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use* / Q000633:toxicity; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy*; D010166:Palliative Care; D010610:Pharyngeal Neoplasms / Q000188:drug therapy*; D013921:Thrombocytopenia / Q000139:chemically induced
D001761:Bleomycin; D008727:Methotrexate
Traitement des carcinomes épidermoïdes oro-pharyngo-laryngés par combinaison de Méthotrexate et de Bléomycine.